We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
25 Feb 2021 - 27 Feb 2021

Raman Spectroscopy Reveals Tumor Resistance to Radiation

By MedImaging International staff writers
Posted on 27 May 2019
Print article
Image: A new study suggests that Raman spectroscopy can help identify a tumor’s resistance to RT (Photo courtesy of JHU).
Image: A new study suggests that Raman spectroscopy can help identify a tumor’s resistance to RT (Photo courtesy of JHU).
A new study suggests that Raman spectroscopy can identify subtle differences in a tumor’s biochemical environment that correlate with its susceptibility to radiation therapy (RT).

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) and the University of Arkansas (UARK; Fayetteville, AR, USA) conducted a murine study to reveal biomolecular changes in tumors induced by radiation, and uncover the latent differences that separate RT-resistant and RT-sensitive tumors. To do so, they grew tumor xenografts in athymic nude mice and quantified the Raman spectroscopic tissue assessments in both untreated and treated tumors by chemometric analysis of the biomolecular differences in the tumor microenvironment.

They found that Raman spectroscopy measurements revealed significant and reliable differences in lipid and collagen content post-radiation in the tumor microenvironment, with consistently greater changes observed in the RT-sensitive tumors. Based on the findings, they then created an algorithm to identify the difference between RT-resistant and nonresistant tumors, and validated it by applying the Raman technique to untreated tumors. The algorithm separated them into RT-sensitive and resistant categories with a success rate of 97%. The study was published on February 28, 2019, in Cancer Research.

“In addition to accurately evaluating tumor response to therapy, the combination of Raman spectral markers potentially offers a route to predicting response in untreated tumors prior to commencing treatment,” concluded lead author Santosh Paidi, MSc, of JHU, and colleagues. “Combined with its non-invasive nature, our findings provide a rationale for in vivo studies using Raman spectroscopy, with the ultimate goal of clinical translation for patient stratification and guiding adaptation of radiotherapy during the course of treatment.”

"This is only the first step of a larger research endeavor to determine how head and neck cancer tumors respond to radiation,” said senior author mechanical engineer Ishan Barman, PhD, of JHU. “The ultimate goal is to build a miniature probe that can fit into a laryngoscope. Hopefully in the future, then, when a clinician performs an endoscopy and looks at a patient's cancerous tumor, they'll be able to determine whether that tumor will even respond to radiation therapy, and that can improve treatment plans.”

Raman spectroscopy is a form of molecular spectroscopy based on Raman scattering. When a beam of light interacts with a material, part of it is transmitted, part it is reflected, and part of it is scattered; over 99% of the scattered radiation has the same frequency as the incident beam, but a small portion of the scattered radiation has frequencies different from that of the incident beam. The scattered radiation contains information on the particular atoms or ions that comprise the molecule, the chemical bonds connect them, the symmetry of their molecule structure, and the physico-chemical environment where they reside.

Related Links:
Johns Hopkins University
University of Arkansas

Print article


Industry News

view channel

New AI-Based Image Analysis Platform Enables Physicians to Analyze CT and MRI Scans in Half the Time of Traditional Methods

The US Food and Drug Administration (FDA) has granted 510(k) clearance for a new image analysis platform that enables physicians to analyze CT and MRI scans in half the time of traditional methods.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.